Science Corporation has successfully implanted its vision-restoring chip in its first patient diagnosed with Stargardt disease, marking a significant step forward in medical device innovation, according to TechCrunch.
Max Hodak, co-founder of Neuralink and involved with Science Corporation, explained at TechCrunch Disrupt how the company's collaboration with the PRIMA project is advancing toward a novel brain-computer interface, potentially revolutionizing treatment for vision impairments.
This development is particularly relevant for Japanese markets, where aging populations and increasing prevalence of retinal diseases highlight the growing demand for advanced medical technologies in ophthalmology and neuroprosthetics.